PMID- 26076563
OWN - NLM
STAT- MEDLINE
DCOM- 20150709
LR  - 20220410
IS  - 1220-4749 (Print)
IS  - 1220-4749 (Linking)
VI  - 53
IP  - 1
DP  - 2015 Jan-Mar
TI  - Four years Follow-up of Patients with Irritable Bowel Syndrome.
PG  - 63-72
AB  - There is little data on the long term evolution of patients with irritable bowel 
      syndrome (IBS) and of associated conditions. We therefore studied the evolution 
      of IBS patients in a single tertiary center during a long interval of time. 
      METHODS: We carried out a retrospective study based on the survey of patients 
      records. We analyzed the records of symptoms, therapy, associated diseases, as 
      consigned at follow-up visits for an interval of 4 years in average (2008-2011). 
      RESULTS: A cohort of 114 patients with IBS diagnosed based on Rome III criteria 
      were included (29 men and 85 women), age 19-85 years (mean age: 43.45 years). 
      Urban patients were predominant. The main three symptoms were: abdominal pain, 
      bowel disorders (constipation, diarrhea) and bloating. IBS--constipation (IBS--C) 
      is associated with a favorable course of symptoms (increasing the number of 
      stools, decrease intensity of abdominal pain and bloating) after treatment and 
      IBS--diarrhea (IBS--D) is associated with variable symptoms after treatment (p = 
      0.031). Using trimebutin or mebeverin in association with other drugs for one 
      month correlates with a favorable evolution of symptoms after treatment and 
      monotherapy is associated with fluctuating symptoms ( p< 0.001). Favorable 
      symptoms are associated with the use of probiotics in combination, but not in 
      monotherapy (p< 0.001). Favorable evolution of symptoms is also associated with 
      the use of anxiolytics in combination. Persistence of symptoms after treatment 
      was correlated with the presence or absence of depression. The absence of 
      depression was correlated with a favorable evolution of symptoms (p = 0.005). 
      IBS-C is associated at limit (marginal significance) with hemorrhoidal disease (p 
      = 0.56). 33 patients (29%)--received monotherapy (trimebutin or mebeverin or 
      probiotics); 81 patients (71%)--received combined therapy: (trimebutin or 
      mebeverin or probiotics) + anxiolytics or proton pump inhibitors (PPI) or 
      nonsteroidal anti-inflammatory (NSAI) or spasmolytics. The most common associated 
      diseases observed in patients with IBS were: depression (27.19%), dyslipidemia 
      (25.43%), hemorrhoidal disease (22.80%) and fibromyalgia (21%). CONCLUSIONS: The 
      highest response rate was obtained with trimebutin or mebeverin + anxiolitics + 
      probiotics. The most frequent disease associated with IBS was depression. Other 
      diseases with a high incidence: dyslipidemia, hemorrhoidal disease and 
      fibromyalgia. Further studies are needed to analyze the link between IBS and some 
      associated diseases.
FAU - Rusu, F
AU  - Rusu F
FAU - Dumitrascu, D L
AU  - Dumitrascu DL
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Rom J Intern Med
JT  - Romanian journal of internal medicine = Revue roumaine de medecine interne
JID - 9304507
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Irritable Bowel Syndrome/*complications/*psychology/therapy
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Time Factors
MH  - Young Adult
EDAT- 2015/06/17 06:00
MHDA- 2015/07/15 06:00
CRDT- 2015/06/17 06:00
PHST- 2015/06/17 06:00 [entrez]
PHST- 2015/06/17 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - 10.1515/rjim-2015-0009 [doi]
PST - ppublish
SO  - Rom J Intern Med. 2015 Jan-Mar;53(1):63-72. doi: 10.1515/rjim-2015-0009.